Covid: Indian vaccine maker seeks permission for first international rollout despite concerns over data
India has already started exporting Covid-19 vaccines to its neighbours
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Bharat Biotech, India’s homegrown vaccine maker, has sought permission for the emergency use of its Covid-19 vaccine, Covaxin, in the Philippines, even as concerns remain over its efficacy and safety data.
Dr Rolando Enrique Domingo, the chief of the Food and Drug Administration in Philippines, said Bharat Biotech on Thursday submitted an application for the emergency use of its Covid-19 vaccines in that country.
Bharat Biotech is the fourth vaccine maker that has applied for emergency use in the Philippines. Covaxin is developed with the Indian Council of Medical Research.
Besides the Philippines, Bharat Biotech has also sought permission from Bangladesh authorities to conduct trials of Covaxin, Reuters news agency reported.
Mahmood-uz-Jahan, a director at the state-run Bangladesh Medical Research Council, confirmed receiving the proposal and stated that its ethics committee would review the application.
If authorities in Bangladesh allow the Covaxin trial, it would be the first trial of any Covid-19 vaccine in Bangladesh.
This comes as China’s Sinovac Biotech’s late-stage trial of a potential vaccine in Bangladesh became uncertain after Dhaka refused to meet the Chinese company’s demand for co-funding.
India gave emergency approval to two vaccines — Covaxin and AstraZeneca/Oxford University’s Covishield — earlier this month for its Covid-19 vaccination programme. But Covaxin’s rollout has been controversial as it got the approval without the crucial data to prove its effectiveness even though Indian authorities claim that it is safe.
Bangladesh’s health secretary Abdul Mannan told Reuters that they at present have no plans to buy Bharat Biotech’s Covaxin. “Our vaccine procurement is in good shape. We are going to start the vaccination in the first week of February,” he said.
So far, only Brazil has announced plans to buy Covaxin doses from India.
According to the Indian government, they have received several requests from “neighbouring and key partner countries” for the supply of Covid-19 vaccines manufactured in India. The government had said that “supplies under grant assistance to Bhutan, Maldives, Bangladesh, Nepal, Myanmar and Seychelles” will begin from 20 January 2021.
On Wednesday, India sent vaccine shots to Bhutan and Maldives - within a week of it started its own vaccination drive.
Bangladesh is scheduled to start getting millions of India-made doses of AstraZeneca’s coronavirus vaccine from Thursday.
Additional reporting by agencies
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments